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Rat small intestinal goblet cell mucins reacting with monoclonal antibody HCM31 increase signiﬁ-
cantly during regeneration from experimental mucosal damage and at the period of expulsion of
parasitic nematode, Nippostrongylus brasiliensis (N.b). The reduction in reactivity of HCM31 with
mucin upon neuraminidase treatment, suggested that HCM31 recognizes sialylated oligosaccharide
on mucin. HCM31-reactive sialomucins are therefore considered to play an important role in the
physiological and pathological changes in the gastrointestinal mucosa. To determine the epitope
for HCM31, oligosaccharide–alditols reacted with HCM31 were obtained from the small intestinal
mucins of N.b-infected rats and puriﬁed by ion-exchange chromatography followed by normal-
phase HPLC. Two HCM31-reactive oligosaccharide-alditols were obtained. Analyses using tandem
mass spectrometry and NMR spectroscopy showed that these oligosaccharides were core 4 mucin-
type oligosaccharides having a common tetrasaccharide sequence, NeuAca2-3(GalNAcb1-4)Galb1-
4GlcNAcb- (Sda blood group antigen). These structures were not found in the small intestinal mucin
oligosaccharides from uninfected rats. This epitope speciﬁcity of HCM31 was also conﬁrmed using
previously established anti-GM2 and anti-Sda antibodies. Taken together, these results strongly sug-
gest that HCM31 speciﬁcally recognizes mucin-type oligosaccharides with the Sda tetrasaccharide
sequence. Immunohistochemical examination of human gastrointestinal tracts showed that
HCM31 site-speciﬁcally stained the goblet cells in normal sigmoid colon and normal rectum, but
the goblet cells stained with HCM31 were reduced in the corresponding cancer tissues. HCM31
seems to be useful for diagnosis of colonic cancer and for examining the function of secretory-type
mucin with Sda antigen.
 2012 Federation of European Biochemical Societies. Published by Elsevier B.V.
Open access under CC BY-NC-ND license.1. Introduction
The gastrointestinal mucus covering the mucosal surface is con-
sidered a major factor in the gastrointestinal defense mechanismal Societies. Published by Elsevier
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wa).against various infectants such as microorganisms, viruses and
parasites [1]. Mucin, a highly O-glycosylated glycoprotein with a
high molecular mass, is a major component of the gastrointestinal
mucus and plays an important role in the mucus barrier covering
mucosal surfaces. Mucins are located site-speciﬁcally in the gastro-
intestinal mucosa according to the distinct type of core protein [2–
4] and attached carbohydrates [5,6]. For the precise characteriza-
tion of individual mucins on a biochemical and physiological basis,
many anti-mucin monoclonal antibodies (mAbs) reacting with
speciﬁc types of carbohydrate chains of gastrointestinal mucins
have been developed in our laboratory, and their properties have
been characterized histochemically and biochemically. Histochem-B.V. Open access under CC BY-NC-ND license.
Fig. 1. Immunohistochemistry for the rat jejunal mucosa with HCM31. Immuno-
staining of the jejunal mucosal specimens of uninfected (a) and N.b-infected (b)–(d)
rats was performed as described in Section 4. The specimens were stained with
HCM31 without additional treatment (a, b), and after de-O-acetylation (c) or a2-
3,6,8-sialidase (d) treatment. Original magniﬁcation 25. Bars = 50 lm.
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ability with mAbs [7–9]. The epitope of an mAb, HIK1083, which
stains mucins from mucus neck cells and pyloric gland cells, has
been determined as a peripheral a-linked GlcNAc on the mucin oli-
gosaccharides [9]. Recently, gastric mucins with this epitope on
their oligosaccharides have been shown to act as a natural antibi-
otic protecting the host from Helicobacter pylori [10] and to play an
essential role in preventing gastric cancer [11]. Thus, epitope anal-
ysis of an mAb that reacts with a speciﬁc oligosaccharide chain
bound to the mucin molecules is needed to clarify the biological
function of the particular oligosaccharides.
The sialomucins with speciﬁc sialylated oligosaccharide deter-
minants are considered to have multiple biological functions. The
sialyl 6-sulfo Lewis x determinant on cell-surface-associated sia-
lomucin is expressed on the high endothelial venules in lymph
nodes as a major ligand for L-selectin in order to allow lymphocyte
homing [12]. Increasing serum levels of sialomucin having the sial-
yl Lewis A determinant are correlated with increasing tumor
metastasis [1]. In gastrointestinal mucosa, sialomucins as mucus
components are secreted by the epithelial cells and have diverse
sialylated oligosaccharide structures. However, the distribution
and the function of individual gastrointestinal sialomucins having
distinct types of sialylated oligosaccharides are poorly understood.
Appropriate mAbs are needed to distinguish the speciﬁc types of
sialomucins.
Recently, we developed an mAb, HCM31, which reacts with
sialylated oligosaccharides of rat small intestinal mucins [13].
Although HCM31 only partially stains the jejunal goblet cells in
normal rat, HCM31-positive goblet cells increased remarkably dur-
ing the processes of regeneration from mucosal damage caused by
the administration of an antineoplastic chemotherapy drug [14]
and nonsteroidal anti-inﬂammatory drugs [15]. Furthermore,
HCM31-positive goblet cells were found to increase remarkably
after infection with the intestinal nematode Nippostrongylus brasil-
iensis (N.b) [16]. HCM31-reactive sialomucins are therefore consid-
ered to play an important role in the physiological and pathological
changes in the gastrointestinal mucosa.
In this study, to characterize the epitope recognized by HCM31,
the oligosaccharides reacting with this mAb were obtained from
small intestinal mucins of N.b-infected rats and their structures
were analyzed by tandem mass spectrometry (MS/MS) and NMR
spectroscopy. The oligosaccharides obtained from uninfected rats
were also analyzed to verify speciﬁc expression of the epitope of
HCM31 after N.b infection. In this paper, the unique epitope se-
quence containing a sialic acid residue and the histochemical dis-
tribution of the sialomucins recognized by this mAb in human
normal and cancer gastrointestinal tract are presented.Fig. 2. TOYOPEARL QAE-550C anion exchange chromatography of the small
intestinal mucin oligosaccharides and the reactivity of oligosaccharides with
HCM31. The same amount of oligosaccharides obtained from uninfected (a) and
N.b-infected (b) rats was loaded onto the column and eluted with water followed by
a linear gradient of 0–0.6 M NaOAc (dashed line). The hexose content (s) of each
fraction was assessed by the phenol-sulfuric acid method. The antigenic activities of
various amounts of the oligosaccharides from the pooled fractions, UN (s), UA1 ()
and UA2 (D) in uninfected rats (c), and IN (s), IA1 () and IA2 (D) in infected rats
(d), were examined by competitive ELISA as described in Section 4. Data are
expressed as mean ± SD from three experiments.2. Results
2.1. Studies of antigenic determinant of HCM31 by the modiﬁcation of
mucin
To characterize the epitope of HCM31, an mAb developed using
human colonic mucin as an antigen, periodate oxidation and tryp-
sin digestion of the puriﬁed rat mucin were performed to degrade
the carbohydrate and peptide moieties, respectively, and then the
residual antigenic activity was tested by ELISA. Periodate oxidation
reduced the antigenic activity to HCM31, whereas trypsin diges-
tion did not affect the reactivity of this mAb (data not shown).
These results indicate that the carbohydrate moieties of the mucin
were involved in the epitope of HCM31.
Fig. 1 shows the immunohistochemical observations of rat jeju-
nal mucosa stained with HCM31. Only a small number of goblet
cells were stained on uninfected rat jejunum (Fig. 1a). In contrast,HCM31-reactive goblet cells increased on day 14 of N.b infection
(Fig. 1b), the time when the worms were expelled from the rats.
Staining was conserved during de-O-acetylation treatment of sialic
acid (Fig. 1c) but was signiﬁcantly reduced after a neuraminidase
treatment, which removes the sialic acid residue frommucin oligo-
saccharide (Fig. 1d). These observations indicate that HCM31 re-
acts with oligosaccharides that have sialic acid that is not O-
acetylated.
2.2. Characterization of HCM31-reactive oligosaccharides from small
intestinal mucin of N.b-infected rats
The oligosaccharides were prepared from rat small intestinal
mucin with or without N.b infection by alkaline borohydride treat-
ment, fractionated by anion exchange chromatography on a TOYO-
PEARL QAE-550C column and then tested for reactivity with
HCM31. From the uninfected rats, one neutral fraction, UN, eluted
with distilled water, and two acidic fractions, UA1 and UA2, eluted
from the column with a gradient of 0.1–0.5 M NaOAc, were ob-
tained (Fig. 2a). Similarly, one neutral fraction, IN, and two acidic
fractions, IA1 and IA2, were obtained from the infected rats
Fig. 4. Mass spectra of oligosaccharide fractions obtained by the ﬁrst-step HPLC.
The oligosaccharide fractions, UA1-5 (upper panel) and IA1-5 (lower panel),
obtained from the uninfected and N.b-infected rats, respectively, were analyzed
byMALDI-TOF/MS (a). The oligosaccharide fractions, UA1-8 (upper panel) and IA1-8
(lower panel), obtained from the uninfected and infected rats were also analyzed
(b). Masses detected in infected but not uninfected rats are indicated by asterisks.
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cantly reacted with HCM31 (Fig. 2d), whereas UA1 did not react
with HCM31, but UA2 did (Fig. 2c). The reactivity of IA2 was higher
than that of UA2. These ﬁndings indicated that the oligosaccha-
rides reacting with HCM31 were acidic; this result is consistent
with the immunohistochemical examination using neuraminidase
treatment (Fig. 1).
UA1 and IA1 were chosen for further analyses because IA1 re-
acted with HCM31 whereas UA1 did not (Fig. 2). UA1 and IA1 were
further puriﬁed by two steps of normal-phase HPLC using TSK-Gel
Amide-80 columns. By the ﬁrst-step HPLC, eight major fractions,
designated as UA1-1 to -8 and IA1-1 to -8, were obtained from
uninfected (Fig. 3a; upper panel) and infected rats (Fig. 3a; lower
panel), respectively. The inhibition assay showed that fractions
IA1-5 and IA1-8 (Fig. 3b) and IA1-6 and IA1-7 (data not shown) sig-
niﬁcantly reacted with HCM31, whereas fractions IA1-2 and IA1-3
(Fig. 3b) and IA1-1 and IA1-4 (data not shown) did not. None of
UA1-1 to -8 reacted with this mAb (data not shown).
The oligosaccharides fractionated by the ﬁrst-step HPLC were
analyzed by MALDI-TOF/MS in negative mode (Table 1). The
masses of the oligosaccharides were distributed from 675 to
1746, corresponding to tri- to nona-saccharides. The sugar compo-
sitions of all the tested oligosaccharides were assigned to the
appropriate acidic oligosaccharide–alditols, bearing either a sulfate
or a sialic acid residue, as well as having GalNAc-ol at the reducing
terminus on the basis of their masses. Because all HCM31-reactive
fractions (IA1-5, -6, -7 and -8 in infected rat) contained sialylated
oligosaccharides, these data support the idea that HCM31 reacted
with sialylated carbohydrate sequence (Fig. 1). Fig. 4a shows MS
spectra of UA1-5 and IA1-5. Two oligosaccharides ( m/z [MH]
of 1097 and 1284) were detected in IA1-5, but not in UA1-5, as also
shown in Table 1. Similarly, three oligosaccharides (m/z [MH] of
1486, 1535 and 1592) were detected in IA1-8, but not in UA1-8
(Fig. 4b, Table 1).
Because it was expected that HCM31-reactive oligosaccharides
were induced by N.b infection, each of IA1-5 and IA1-8 was further
puriﬁed by the second-step HPLC and characterized. Fraction IA1-5
separated into ﬁve fractions, designated IA1-5a, -5b, -5c, -5d and -
5e (Fig. 5a; lower panel), corresponding to m/z [MH] of 1121,
1097, 1186, 1284 and 1186, respectively (Table 2). Fraction IA1-8Fig. 3. First-step HPLC of oligosaccharide fractions of uninfected and N.b-infected
rats using Tskgel Amide-80 columns and the reactivity of oligosaccharides with
HCM31. Fractions UA1 (upper panel) and IA1 (lower panel) were loaded on the
column and then eluted with a 30 min linear gradient of acetonitrile (68–55%) (a).
Absorbance was monitored at 210 nm. The antigenic activities of various amounts
of the oligosaccharides from puriﬁed oligosaccharide fractions, IA1-2 (s), IA1-3(),
IA1-5 (D) and IA1-8 (N), in infected rats were examined by competitive ELISA (b), as
described in Section 4. Data are expressed as mean ± SD from three experiments.
Fig. 5. Second-step HPLC of oligosaccharide fractions of uninfected and N.b-infected
rats using TSKgel Amide-80 columns. Fractions, UA1-5 (a; upper panel) and UA1-8
(b; upper panel) from uninfected rats, and IA1-5 (a; lower panel) and IA1-8 (b;
lower panel) from N.b-infected rats, were eluted with 74% acetonitrile under
isocratic conditions. The absorbance was monitored at 210 nm.
Fig. 6. The reactivity of puriﬁed oligosaccharides after second-step HPLC with
HCM31. The antigenic activities of various amounts of puriﬁed oligosaccharides,
IA1-5d (s) and IA1-8b (), in infected rats were examined by competitive ELISA as
described in Section 4. Data are expressed as mean ± SD from two experiments.
Table 1
Differences of mucin oligosaccharide separated by the ﬁrst-step HPLC between uninfected and N.b-infected rats: identiﬁed by MALDI-TOF/MS. Oligosaccharides detected only in
the infected rats are noted in bold text.
Fraction [MH]- (m/z) Expected composition of oligosaccharide-alditols Uninfected (U) Infected (I)
A1-1 675 (NeuAc)(Hex)GalNAc-ol + +
813 (SO3H)(dHex)(Hex)(HexNAc)GalNAc-ol + +
A1-2 675 (NeuAc)(Hex)GalNAc-ol + 
878 (NeuAc)(Hex)(HexNAc)GalNAc-ol + +
894 (NeuGc)(Hex)(HexNAc)GalNAc-ol  +
975 (SO3H)(dHex)(Hex)2(HexNAc)GalNAc-ol  +
1016 (SO3H)(dHex)(Hex)(HexNAc)2GalNAc-ol + +
1073 (SO3H)(Hex)(HexNAc)3GalNAc-ol  +
1081* (NeuAc)(Hex)(HexNAc)2GalNAc-ol  +
A1-3 878 (NeuAc)(Hex)(HexNAc)GalNAc-ol + +
894 (NeuGc)(Hex)(HexNAc)GalNAc-ol + +
975 (SO3H)(dHex)(Hex)2(HexNAc)GalNAc-ol + +
1016 (SO3H)(dHex)(Hex)(HexNAc)2GalNAc-ol + +
1081* (NeuAc)(Hex)(HexNAc)2GalNAc-ol  +
1097 (NeuGc)(Hex)(HexNAc)2GalNAc-ol  +
1121 (SO3H)(dHex)2(Hex)2(HexNAc)GalNAc-ol + +
1178 (SO3H)(dHex)(Hex)2(HexNAc)2GalNAc-ol  +
A1-4 975 (SO3H)(dHex)(Hex)2(HexNAc)GalNAc-ol + +
1121 (SO3H)(dHex)2(Hex)2(HexNAc)GalNAc-ol + +
1178 (SO3H)(dHex)(Hex)2(HexNAc)2GalNAc-ol  +
A1-5 1097 (NeuGc)(Hex)(HexNAc)2GalNAc-ol  +
1121 (SO3H)(dHex)2(Hex)2(HexNAc)GalNAc-ol + +
1178 (SO3H)(dHex)(Hex)2(HexNAc)2GalNAc-ol + +
1186* (NeuAc)(dHex)(Hex)2(HexNAc)GalNAc-ol + +
1284* (NeuAc)(Hex)(HexNAc)3GalNAc-ol  +
1324 (SO3H)(dHex)2(Hex)2(HexNAc)2GalNAc-ol + 
A1-6 1186* (NeuAc)(dHex)(Hex)2(HexNAc)GalNAc-ol + +
1324 (SO3H)(dHex)2(Hex)2(HexNAc)2GalNAc-ol + +
1381 (SO3H)(dHex)(Hex)2(HexNAc)3GalNAc-ol + +
1389* (NeuAc)(dHex)(Hex)2(HexNAc)2GalNAc-ol  +
A1-7 1178 (SO3H)(dHex)(Hex)2(HexNAc)2GalNAc-ol + +
1202 (NeuGc)(dHex)(Hex)2(HexNAc)GalNAc-ol + 
1324 (SO3H)(dHex)2(Hex)2(HexNAc)2GalNAc-ol + +
1340 (SO3H)(dHex)(Hex)3(HexNAc)2GalNAc-ol + 
1381 (SO3H)(dHex)(Hex)2(HexNAc)3GalNAc-ol  +
1389* (NeuAc)(dHex)(Hex)2(HexNAc)2GalNAc-ol + +
1486 (SO3H)(dHex)2(Hex)3(HexNAc)2GalNAc-ol + +
A1-8 1486 (SO3H)(dHex)2(Hex)3(HexNAc)2GalNAc-ol  +
1535* (NeuAc)(dHex)2(Hex)2(HexNAc)2GalNAc-ol  +
1551* (NeuAc)(dHex)(Hex)3(HexNAc)2GalNAc-ol + +
1592* (NeuAc)(dHex)(Hex)2(HexNAc)3GalNAc-ol  +
1689 (SO3H)(dHex)2(Hex)3(HexNAc)3GalNAc-ol + +
1746 (SO3H)(dHex)(Hex)3(HexNAc)4GalNAc-ol + +
* The compositions were determined by MS/MS analysis in terms of whether they contained NeuAc or NeuGc.
Table 2
Oligosaccharides separated by the second-step HPLC from small intestine in N.b-
infected rats: identiﬁed by MALDI-TOF/MS.
Fraction [M-H]-(m/z) Expected composition of oligosaccharide-alditols
IA1-5a 1121 (SO3H)(dHex)2(Hex)2(HexNAc)GalNAc-ol
IA1-5b 1097 (NeuGc)(Hex)(HexNAc)2GalNAc-ol
IA1-5c 1186 (NeuAc)(dHex)(Hex)2(HexNAc)GalNAc-ol
IA1-5d 1284 (NeuAc)(Hex)(HexNAc)3GalNAc-ol
IA1-5e 1186 (NeuAc)(dHex)(Hex)2(HexNAc)GalNAc-ol
IA1-8a 1486 (SO3H)(dHex)2(Hex)3(HexNAc)2GalNAc-ol
IA1-8b 1592 (NeuAc)(dHex)(Hex)2(HexNAc)3GalNAc-ol
IA1-8c 1535 (SO3H)(dHex)2(Hex)3(HexNAc)2GalNAc-ol
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(Fig. 5b; lower panel), corresponding to m/z [MH] of 1486, 1592
and1535, respectively (Table 2). IA1-5d and IA1-8bweremajor frac-
tions among IA1-5 and IA1-8, respectively, and their amounts were
sufﬁcient for inhibition assay with HCM31. The inhibition assay
showed that IA1-5d and IA1-8b signiﬁcantly reacted with HCM31
(Fig. 6). Because UA1-5 and UA1-8 did not contain the oligosaccha-
rides assigned as IA1-5d and IA1-8b, respectively (Fig. 5), this result
conﬁrmed that the two HCM31-reactive oligosaccharides are abun-
dantly expressed by N.b infection.2.3. Structural analysis of sialylated oligosaccharides recognized by
HCM31
To obtain further structural information for the epitope of
HCM31, puriﬁed HCM31-reactive oligosaccharides, IA1-5d and
IA1-8b, were analyzed by MS/MS, amino sugar analysis and NMR
spectroscopy. MS/MS analyses of the oligosaccharides were per-
formed using positive mode after methylesteriﬁcation of the sialic
acid residue.
2.3.1. Structural analysis of IA1-5d
Amino sugar analysis of IA1-5d showed that the molar ratio
of GalNAc-ol, GalNAc and GlcNAc was 1.0:1.0:2.1. Fig. 7a shows
the fragmentation spectrum of IA1-5d ( m/z 1322 as [M+Na]+) by
MS/MS analysis. In this spectrum, the core 4 structure was iden-
tiﬁed by the diagnostic ion Y2b at m/z 652. The series of Bi ions
at m/z 591 (HexNAc-Hex-HexNAc), 693 (NeuAc-Hex-HexNAc or
NeuAc-[HexNAc-]Hex) and 896 (NeuAc-[HexNAc-]Hex-HexNAc)
and Y1a/Y3b’’ ion at m/z 916 (NeuAc-Hex-HexNAc-GalNAc-ol) al-
low reconstruction of the sequence as follows: NeuAc-(GalNAc-
)Gal-GlcNAc-[GlcNAc-]GalNAc-ol illustrated in Fig. 7a. Fig. 8a
shows the one-dimensional1H NMR spectrum of IA1-5d (0.15
mg). In the spectrum, b-anomeric resonances (4.69, 4.56, 4.52
Fig. 7. MS/MS spectra of oligosaccharides, IA1-5d (a) and IA1-8b (b). Precursor ions
are indicated by an asterisk. Fragmentation uses the Domon and Costello nomen-
clature [37].
Table 3
Chemical shifts of each sugar component. Chemical shifts labeled with an asterisk
indicate occurrence of glycosylation shift.
IA1-5d IA1-8b Standardsb
Sugar 1H 13C 1H 13C 13C
GalNAc-ol
Position 1 3.58/3.84 62.7 3.58/3.83 62.7 61.5
Position 2 4.24 51.4 4.24 51.3 51.5
Position 3 3.94* 76.6* 3.93* 77.0* 68.4
Position 4 3.47 69.1 3.45 69.3 69.4
Position 5 4.20 67.7 4.17 67.9 69.8
Position 6 3.66/3.86* 71.0* 3.66/3.86* 71.1* 63.2
Ac-CH3 2.04 22.2 2.06 22.2 21.7
b-GlcNAc3a
Position 1 4.56 102.3 4.53 101.5 101.9
Position 2 3.71 55.8 3.76 55.1 55.4
Position 3 3.55 73.4 3.63 72.3 73.9
Position 4 3.44 69.9 3.73* 73.9* 69.9
Position 5 3.42 75.6 3.44 75.0 75.8
Position 6 3.71/3.91 61.0 3.76 /3.97 61.0 60.7
Ac-CH3 2.00 22.0 2.01 21.9 21.9
b-GlcNAc6a
Position 1 4.52 101.5 4.52 102.7 101.9
Position 2 3.72 54.8 3.71 54.8 55.4
Position 3 3.66 74.6 3.67 74.6 73.9
Position 4 3.73* 73.9* 3.72* 73.9* 69.9
Position 5 3.56 74.7 3.55 74.9 75.8
Position 6 3.76/3/96 60.4 3.73 /3.95 60.4 60.7
Ac-CH3 2.02 22.1 2.02 22.2 21.9
b-Gal4,3a
Position 1 4.62 100.1 103.7
Position 2 3.57* 76.3* 70.7
Position 3 3.81 73.4 72.7
Position 4 3.86 69.0 68.6
b-Gal4,6a
Position 1 4.51 102.5 4.51 102.5 103.7
Position 2 3.31 70.0 3.31 69.9 70.7
Position 3 4.11* 74.2* 4.12* 74.2* 72.7
Position 4 4.07* 77.1* 4.08* 77.1* 68.6
a-Fuc2,4a
Position 1 5.17 99.3 99.4
Position 2 3.74 67.9 67.8
Position 5 4.22 66.4 66.4
CH3 1.19 15.2 15.2
b-GalNAc
Position 1 4.69 102.7 4.69 102.6 99.0
Position 2 3.87 52.2 3.88 52.2 52.0
Position 3 3.64 71.3 3.64 71.1 70.5
Position 4 3.86 67.9 3.86 67.7 67.5
Ac-CH3 1.97 22.5 1.97 22.5 22.3
a-NeuAc
Position 1 174.3 174.2 171.6
Position 2 101.6 101.6 99.4
Position 3(ax) 1.89 36.8 1.89 36.8 39.1
Position 3(eq) 2.62 36.8 2.62 36.8 39.1
Position 4 3.73 68.1 3.73 68.1 67.5
Ac-CH3 1.99 22.3 1.99 22.3 22.2
a
A superscript at a monosaccharide residue indicates to which position of the
adjacent monosaccharide it is glycosidically linked. Two superscripts map out the
pathway from the residue toward the GalNAc-ol residue.
b
Standards are a- and b-methyl derivatives of each component sugar except Gal-
NAc-ol.
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GalNAc, two residues of the b-linked GlcNAc, and one residue
of the b-linked Gal, respectively, by their coupling to a high-ﬁeld
H-2 resonance and the pattern of the cross-peaks in the TOCSY
spectrum (data not shown). The carbohydrate composition of
IA1-5d obtained from the NMR spectrum agreed with that ex-
pected by the data obtained from the molecular mass and amino
sugar analyses. From the13C chemical shifts of the heteronuclear
multiple-quantum coherence spectroscopy (HMQC) spectra of
IA1-5d (Table 3), no substitution could be observed on one of
the two b-linked GlcNAc residues, indicating that this GlcNAc
residue is present at the non-reducing terminal in this structure.
Another b-linked GlcNAc is attached at position 4 (3.73 ppm),
which could be proved by the lower ﬁeld changes in the HMQC
spectrum (+4.0 ppm) of GlcNAc compared with that of the stan-
dard b-methylated GlcNAc [9]. The residues of the b-linked Gal
and GalNAc-ol at the reducing terminus showed the glycosyla-
tion shift at positions 3 and 4, and positions 3 and 6, respec-tively, on the basis of13C chemical shift assessment. The
existence of residues of NeuAc and b-linked GalNAc, and the
substitutions at positions 3 and 4 of the b-linked Gal indicated
that the oligosaccharide has a terminal sequence, NeuAca2-
3(GalNAcb1-4)Galb- [17]. To elucidate whether NeuAc-containing
branch attached at position C3 or C6 of GalNAc-ol, the C–C bond
of the GalNAc-ol at the reducing terminal was cleaved at posi-
tions C4 and C5 by mild periodate oxidation. The molecular
masses of the fragments were estimated by MALDI-TOF/MS.
Two fragments, corresponding to NeuAc-(GalNAc)Gal-GlcNAc-
O–CH2–CHO and GlcNAc-O–CH(CHO)–CH(NHCOCH3)–CH2–CHO,
were obtained. This indicated that the NeuAc-containing branch
Fig. 8. One-dimensional 1H NMR spectra of oligosaccharides, IA1-5d (a) and IA1-8b (b).
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nally, it was proposed that oligosaccharide IA1-5d had the fol-
lowing structure:2.3.2. Structural analysis of IA1-8b
Fig. 7b shows the fragmentation spectrum of IA1-8b ( m/z
1630 as [M+Na]+). This oligosaccharide has the same branch
having NeuAc as IA1-5d because the series of Bi ions at m/z
591, 693 and 896 and Y1a/Y3b’’ ion at m/z 916 were also de-
tected. The existence of Y1a/Y2b or Y2a/Y1b ion at 449 (Hex-
NAc-GalNAc-ol), but not at 408 (Hex-GalNAc-ol), indicated that
this structure is based on a core 3 or 4 structure. The B3a ion
at 534 indicated a fragment of (dHex)Hex-HexNAc. From these
fragment ions and data of amino sugar analysis (GalNAc-ol:Gal-
NAc:GlcNAc, 1.0:1.0:2.0), the structure was estimated to be Neu-
Ac-(GalNAc-)Gal-GlcNAc-[(Fuc-)Gal-GlcNAc-]GalNAc-ol. Fig. 8b
shows the one-dimensional1H NMR spectrum of IA1-8b (0.2
mg). b-anomeric resonances (4.69, 4.62, 4.53, 4.52 and 4.51
ppm) were recognized as one residue of the b-linked GalNAc,
one of two residues of the b-linked Gal, two residues of the b-
linked GlcNAc, and one residue of another b-linked Gal, respec-
tively, by their coupling to a high-ﬁeld H-2 resonance and the
TOCSY spectrum. One lower-ﬁeld a-anomeric resonance was alsorecognized as one residue of the a-linked Fuc by a method sim-
ilar to that described above. The Fuc residue attached to the one
b-linked Gal residue at position 2 (3.57 ppm), which could be
proved by the lower-ﬁeld changes in the HMQC spectrum
(+5.6 ppm) of Gal [9]. The glycosylation shifts were observed
at positions 3 and 6, positions 3 and 4, and position 4 of the
GalNAc-ol, another b-linked Gal and two residues of the b-linked
GlcNAc, respectively, on the basis of the13C chemical shift
assessment (Table 3). The structure was conﬁrmed by the mild
periodate oxidation: two fragments, corresponding to NeuAc-
(GalNAc)Gal-GlcNAc-O–CH2–CHO and Fuc-Gal-GlcNAc-O–
CH(CHO)–CH(NHCOCH3)–CH2–CHO, were obtained from IA1-8b.
The structure of IA1-8b was estimated as follows:2.4. Structural analysis of other sialylated oligosaccharides
Because IA1-6 and IA1-7 also reacted with HCM31, MS/MS anal-
yses of sialylated oligosaccharides contained in these fractions
were achieved after the ﬁrst-step HPLC. The fragmentation spec-
trum of IA1-6 ( m/z 1427 as [M+Na]+) included the series of Bi ions
at m/z 591, 693 and 896 and Yi ion at m/z 916 (data not shown),
which indicated the presence of the sequence, NeuAc-(Hex-
NAc)Gal-GlcNAc-GalNAc-ol. Y ions at m/z 408 and 449 indicated
that this oligosaccharide had a core 2 structure. Therefore, the
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)Gal-GlcNAc-]GalNAc-ol, having core 2 and a terminal sequence,
NeuAca2-3(GalNAcb1-4)Galb1-4GlcNAcb-. Although IA1-7 reacted
with HCM31, the MS/MS data did not allow reconstruction of the
sequence owing to the low intensity of the fragment ions.
MS/MS analyses of sialylated oligosaccharides in UA1-1 to -8
and IA1-1 to -4, none of which reacts with HCM31, were also
achieved (Table S1). The fragmentation spectra for the sialylated
oligosaccharides showed that all oligosaccharides contained Y ion
at m/z 408, which indicated the presence of a core 1 or 2 structure,
but not at 591 (HexNAc-Hex-HexNAc) and 896 (NeuAc-(HexNAc-
)Hex-HexNAc). These results suggest that the HCM31-unreactive
sialylated oligosaccharide fractions contain neither the core 4
structure nor NeuAc-(GalNAc-)Gal-GlcNAc- sequence. This result
strongly suggests that the core 4 oligosaccharides having a tetra-
saccharide sequence, NeuAca2-3(GalNAcb1-4)Galb1-4GlcNAcb-
(Sda antigen), include the epitope of HCM31.
2.5. Comparison of antigenic speciﬁcities of HCM31 with anti-Sda and
anti-GM2 monoclonal antibodies
Because the Sda antigen, NeuAca2-3(GalNAcb1-4)Galb1-[4Glc-
NAcb]-, has a common terminal trisaccharide sequence with
GM2 ganglioside, NeuAca2-3(GalNAcb1-4)Galb1-[4Glcb-Cer], the
antigenic speciﬁcity of HCM31 was compared with previously
established mAbs, GMB28 [18] and KM694 [19,20]. GMB28 specif-
ically reacts with GM2 ganglioside. KM694 has been shown to de-
tect Sda active carbohydrate epitopes, in addition to GM2
ganglioside, efﬁciently. We found that KM694 bound to the mucin
obtained from N.b-infected rats as well as HCM31 did, and the
reactivity of KM694 to infected mucin was higher than that ob-
tained from non-infected rats (Fig. S1a). A commercial GM2 gangli-
oside was recognized by GMB28 and KM694, but not by HCM31
(Fig. S1b). The antigenic speciﬁcities of these mAbs are summa-
rized in Table S2.
2.6. Immunohistochemical study of human gastrointestinal tract with
HCM31
Fig. 9 shows the immunohistochemical reactivity of HCM31
with various sections of human gastrointestinal mucosa. There
were no epithelial cells stained with HCM31 in the epithelia of
the esophagus, gastric fundus (data not shown), gastric pylorus
(Fig. 9a) and duodenum (Fig. 9b). The bronchial mucosa was also
negative with this mAb (data not shown). In the upper part of crypt
of the right-side colon (cecum), the goblet cells were only partly
stained with HCM31 (Fig. 9c). The change of stainability was less
apparent on the cancer tissues of cecum. In the left-sided colon
(sigmoid colon, Fig. 9d; and rectum, data not shown), most goblet
cells showed immunoreactivity with HCM31. A deeper upper gra-
dient with enhanced upper expression was evident. HCM31-reac-
tive goblet cells decreased with malignant change in the sigmoid
colon (Fig. 10) and the rectum (data not shown). The results ob-
tained in normal and cancer human gastrointestinal tracts are
summarized in Table S3.
3. Discussion
In the present study, two HCM31-reactive sialylated oligosac-
charides were obtained from the small intestinal mucin of N.b-in-
fected rats. These were completely characterized as core 4 hexa-
and octa-saccharides both having Sda blood group antigen, Neu-
Aca2-3(GalNAcb1-4)Galb1-4GlcNAcb-. To our knowledge, the core
4 oligosaccharides having the Sda antigen have not been described
previously. This study indicates that the Sda tetrasaccharide se-quence is necessary as an epitope determinant of HCM31 for the
following reasons. (a) The two HCM31-reactive oligosaccharides,
IA1-5d and IA1-8b, contain this common tetrasaccharide sequence.
(b) The reduction in the reactivity with HCM31 of the mucin by the
neuraminidase treatment showed that HCM31 recognized the
sialylated oligosaccharides (Fig. 1). (c) Because HCM31 did not re-
act with GM2 ganglioside, NeuAca2-3(GalNAcb1-4)Galb1-4Glcb-
Cer (Fig. S1), the GlcNAcb residue on the Sda antigen is a necessary
part of the epitope. This idea is also supported by the fact that
HCM31 did not react with IA1-2 and -3 (Fig. 3b), which seemed
to include the Sda-like trisaccharide sequence, NeuAca2-3(Gal-
NAcb1-4)Galb-, without the GlcNAcb residue (Table S1) [21]. (d)
HCM31 did not react with the oligosaccharide fractions IA1-1 to
-4 obtained from N.b-infected animals, and all the UA1 fractions,
UA1-1 to -8, obtained from the uninfected animals, fractionated
by the ﬁrst-step HPLC. The MS/MS analysis showed that the frag-
ment ions derived from the Sda antigen could not be detected in
these fractions (Table S1). (e) The sialylated oligosaccharide, Fuc-
Gal-[NeuAc-Gal-GlcNAc-]GalNAc-ol, in UA1-5 of uninfected rat mu-
cin seemed to include NeuAca2-3Galb1-4GlcNAcb- sequence
(Table S1). Thus, the GalNAc residue linked to Gal in the Neu-
Aca2-3Galb1-4GlcNAc sequence via b1-4 linkage could be required
for sufﬁcient reaction with HCM31.
Both IA1-5d and IA1-8b have a core 4 structure. However, the
core 4 structure may be unnecessary as an epitope determinant
of HCM31. Although HCM31 was developed using human colonic
mucin as an antigen [13], the Sda antigens are expressed on core
3 oligosaccharides, but not on core 4 oligosaccharides, in human
colonic mucin [22]. Therefore, HCM31 may also recognize core 3
oligosaccharide having Sda antigen. Furthermore, HCM31 may rec-
ognize core 2 oligosaccharide having the Sda antigen in fraction
IA1-6 from the infected rat mucin. Thus, the type of core structure
seems not to relate to the reactivity with HCM31. In conclusion, we
propose that HCM31 recognizes the tetrasaccharide sequence,
NeuAca2-3(GalNAcb1-4)Galb1-4GlcNAcb-.
Some mAbs against Sda antigen, CT1 and CT2, were developed
by Conzelmann and Lefrancois [23], which react with a terminal
trisaccharide sequence, NeuAca2-3(GalNAcb1-4)Galb-. Previously
reported KM694 [19] and KM531 [24] react with both GM2 gangli-
oside and a neolacto-series Sda glycolipid, which share oligosac-
charide NeuAca2-3(GalNAcb1-4)Galb structures at their non-
reducing terminals. Therefore, the epitope determinant of KM694
and KM531 seems to be the trisaccharide sequence, the same as
that of CT1 and CT2. In the present study, we showed that
KM694 also recognized the mucins (Fig. S1). On the other hand,
HCM31, developed using human colonic mucin as an immunogen,
reacted with rat goblet cell mucins having Sda, but not GM2. The
difference of antigenic activities is assumed to be attributable to
their epitope saccharide sequences. HCM31 and KM694 probably
recognize the terminal tetrasaccharide and trisaccharide without
inner GlcNAcb, respectively, of the Sda tetrasaccharide attached
to the mucin. As an anti-GM2 mAb, GMB28, did not react with
the mucins (Fig. S1), the Glcb residue on GM2 seems to be a neces-
sary part of the epitope for this mAb. Although the biological func-
tion of Sda tetrasaccharide on mucin remains unknown, HCM31
will contribute to clarify this issue.
The Sda antigen expressed as a glycolipid on chief cells disap-
peared along with the malignant changes in human gastric mucosa
[20]. Kawamura et al. [19] reported that metastasis of human gas-
trointestinal cancer cells was reduced by expression of the Sda
antigen on their surface. In the present study, HCM31 did not stain
the epithelial cells on the human gastric mucosa. The tissue ﬁxa-
tion method used in our study might not ﬁx the membrane glyco-
lipids including Sda antigen. Meanwhile, HCM31 extensively
stained the secretory granules of goblet cells in sigmoid colon
and rectum (Fig. 9). Furthermore, the stainability with HCM31 dis-
Fig. 9. Immunostaining of the human gastrointestinal mucosae with HCM31.
Immunostaining of the normal tissues [pylorus (a), duodenum (b), cecum (c) and
sigmoid colon (d)]. Original magniﬁcation 50. Bars = 50 lm.
Fig. 10. Histochemical observation of the human colonic mucosa with malignant
change. H&E staining (a) and immunostaining with HCM31 (b) for a sigmoid colon
cancer specimen. The malignant change is seen on the left side of the picture, while
normal mucosal structure is seen on the right side. Original magniﬁcation 50. Bars
= 50 lm.
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might be useful as a negative marker for colonic cancer. This is con-
sistent with the data that Sda antigen on core 3-type mucin oligo-
saccharide [22] and b1-4-N-acetylgalactosamine-transferase (b1-
4GalNAcT), responsible for the Sda antigen biosynthesis, are co-ex-
pressed on human colonic mucosa, but this expression declines
along with malignant changes [25]. However, it is still unknown
how the secretory-type mucin having this antigen acts on the gas-
trointestinal mucosa. HCM31 seems to be useful for examining the
function of secretory-type mucin with Sda antigen.
Recently, we reported that goblet cell sialomucins that reacted
with HCM31 in the rat jejunal mucosa increased up to 16 days after
N.b infection, the time when the worms were expelled from the
rats [16]. No similar change could be observed by another mAb,
PGM34, which extensively stains goblet cells in the rat small intes-
tine, and recognizes sulfated oligosaccharide [26]. Karlsson et al.
[21] reported that sialylated tetra- and penta-saccharides having
Sda-like trisaccharide, NeuAc/NeuGca2-3(GalNAcb1-4)Galb-, were
expressed in small intestinal mucin of N.b-infected rats. In the
present study, NeuAc/NeuGc-(HexNAc-)Gal-[GlcNAc-]GalNAc-ol
appeared in A1 fraction by N.b infection in addition to Sda-contain-
ing oligosaccharides. Thus, sialomucins with Sda antigen-related
oligosaccharides are associated with worm expulsion. The present
study also showed that the core 4 mucin-type oligosaccharides
having sialic acid with or without Sda sequence are expressed upon
infection (Fig. 5 and Table S1). b1-3GlcNAc-transferase (b1-3GlcN-
AcT) and b1-6GlcNAc-transferase (b1-6GlcNAcT) are needed for
the synthesis of core 4 glycan [27]. Therefore, expression of these
transferases may increase with infection, but further studies are
needed to conﬁrm these changes.In summary, HCM31 is a very useful tool for recognizing the
characteristic sialomucin bearing the Sda blood group antigen in
immunochemical and immunohistochemical methods. Goblet cells
producing the speciﬁc sialomucins increased during process of
expulsion of parasitic nematode in rat small intestine and de-
creased with malignant change in human colon. Further research
using this mAb could elucidate the biological signiﬁcance of sial-
omucins containing the Sda tetrasaccharide in health and disease.
4. Materials and methods
4.1. Reagents
Bio-Gel A-1.5m was obtained from Bio-Rad Laboratories (Rich-
mond, CA, USA). Dowex-50 was purchased from Dow Chemical
Company (Midland, MI, USA). TOYOPEARL QAE-550C resin and
TSKgel Amide-80 column were purchased from Tosoh Co. Inc. (To-
kyo, Japan). A graphitized carbon column (GL-Pak Carbograph, 150
mg/3 ml) was obtained from GL-Science (Tokyo, Japan).
The mAb, HCM31 (antibody subclass IgG1 j), was prepared as
previously described [13]. The anti-GM2 mAb, GMB28, was kindly
provided by Drs. I. Kawashima and K. Ogura (Tokyo Metropolitan
Institute of Medical Science). The anti-Sda mAb, KM694, was kindly
provided by Tokyo Research Park, Kyowa Hakko Kirin Co. Ltd.
(Machida, Japan).
4.2. Preparation of small intestinal mucin from uninfected and N.b-
infected rats
N.b was maintained in our laboratory as previously described
[16]. Eight-week-old male Wistar rats (weighing 200–250 g, SLC,
Shizuoka, Japan) were used. The rats were inoculated subcutane-
ously with the third-stage larvae (L3) of N.b (2000 L3/rat). The rats
were sacriﬁced after 24 h of fasting at 16 days after the inoculation,
and their small intestines were removed. The small intestines were
also obtained from uninfected rats. The small intestines were suc-
cessively cut open, washed with saline and then lyophilized fol-
lowed by weighing. Mucins were extracted from the pulverized
small intestine using 2% Triton X-100 in 50 mM Tris–HCl (pH
7.2), isolated with a Bio-Gel A-1.5 m column and precipitated with
ethanol as described previously [28]. This study was conducted in
accordance with the guidelines of the Animal Laboratory Center of
Kitasato University School of Medicine.
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intestinal mucin
Alkaline borohydride treatment of the puriﬁed rat small intesti-
nal mucin was carried out according to the method of Carlson [29]
with 0.05 M NaOH in 1.0 M NaBH4 at 50 C for 24 h. After acidiﬁ-
cation, the reaction mixture was applied onto a column of Dowex-
50 (H+-form) to remove sodium and the peptides. The passed frac-
tions were evaporated and borate was removed by repeated evap-
oration with acidiﬁed methanol. After being redissolved in water,
the oligosaccharide solution was subsequently applied onto an an-
ion-exchange column of TOYOPEARL QAE-550C. The column was
washed with distilled water and eluted with a linear gradient of
0–0.6 M NaOAc. The efﬂuent was monitored by hexose content
[30]. The fractions were collected and desalted on a graphitized
carbon column using 25% acetonitrile for the neutral oligosaccha-
rides or 25% acetonitrile containing 0.05% triﬂuoroacetic acid for
the acidic ones as eluting solvent [31].
4.4. Normal-phase HPLC
Two-step normal-phase HPLC using TSKgel Amide-80 columns
was employed. In the ﬁrst step, the columns (7.8 mm  300 mm
 2 columns) were equilibrated with 68% (v/v) CH3CN in 2.5 mM
NaH2PO4, and the gradient was initiated after injection and de-
creased to 55% CH3CN over 30 min at a ﬂow rate of 2.0 ml/min.
In the second step (4.6 mm  250 mm  2 columns), the fractions
obtained from the ﬁrst-step HPLC were rechromatographed under
isocratic conditions of 74% CH3CN for 1 h at a ﬂow rate of 1.0 ml/
min. UV absorption of the efﬂuent solution was monitored at 210
nm. For the removal of NaH2PO4, the fractions were chromato-
graphed using a graphitized carbon column as described above.
4.5. Amino sugar analysis
Amino sugar analysis was performed as previously described
[32] after the oligosaccharides were hydrolyzed with 6 M HCl at
98 C for 4 h using the Waters’ Pico-Tag Workstation.
4.6. Mass spectrometry
The molecular masses of the oligosaccharides were analyzed by
matrix-assisted laser desorption/ionization-time of ﬂight mass
spectrometry (MALDI-TOF/MS) using an autoﬂex III TOF/TOF
instrument (Bruker Daltonik GmbH, Bremen, Germany) in reﬂector
mode by summarizing 1000 signal spectra (5  200 shots) with a
50 Hz laser applying the following instrument settings: ion source
1: 19.00 kV, ion source 2: 16.60 kV, lens: 8.55 kV, reﬂector 1: 21.00
kV, reﬂector 2: 9.70 kV, reﬂector detector: 1400 V, suppression up
to 400 Da by deﬂection. Then, MS/MS spectra were further mea-
sured with an Autoﬂex III TOF/TOF instrument in LIFT (MS/MS)
mode using the following instrument settings: ion source 1: 6.00
kV, ion source 2: 5.30 kV, lens: 3.00 kV, reﬂector 1: 27.00 kV, reﬂec-
tor 2: 11.65 kV, lift 1: 19.00 kV, lift 2: 4.20 kV, reﬂector detector:
1400 V. Each sample was mixed with an equal volume of 2,5-dihy-
droxy benzoic acid dissolved in distilled water/CH3CN (1:1, v/v) at
10 mg/ml as the matrix solutions [33]. Two ll of this mixture was
then applied to a stainless steel target plate and air-dried at room
temperature before the target was introduced into the
spectrometer.
4.7. Methylesteriﬁcation of sialylated oligosaccharides
Sialylated oligosaccharides were methylesteriﬁed for MS/MS
analysis in accordance with the procedure by Powell and Harvey
[34]. The oligosaccharides were dissolved in 1 ll of dimethyl sulf-oxide, mixed with 1 ll of methyl iodide and allowed to react for 2 h
at room temperature. Unreacted methyl iodide was removed and
dried under a gentle stream of nitrogen.
4.8. NMR spectroscopy
The NMR spectra were obtained using Varian INOVA 600 or Var-
ian NMR System 600 NMR spectrometer (Varian Associates, Palo
Alto, CA, USA) equipped with a1H{15N–31P} pulse ﬁeld gradient
(PFG) indirect-detecting probe. Standard pulse sequences were
used throughout. The proton NMR spectrum was assigned through
PFG multiple-quantum-correlation spectroscopy and one-dimen-
sional HOHAHA spectroscopy. The13C assignments were made
from an HMQC spectrum obtained with carbon decoupling. The
lyophilized powder of the puriﬁed oligosaccharides was dissolved
in deuterium oxide (2H2O) and evaporated to exchange the unsta-
ble1H with2H. The evaporation and dissolution were repeated ﬁve
times and the sample was ﬁnally dissolved in 0.04 or 0.15 ml
of2H2O and then subjected to NMR spectroscopy using nano-probe
or Shigemi tube, respectively. Chemical shifts of the reduced oligo-
saccharide structures were identiﬁed with reference to those de-
scribed by Kamerling and Vliegenthart [17]. NMR spectra of a-
methyl-N-acetylneuraminic acid (Nagara Science, Gifu, Japan)
and b-para-nitrophenyl-N-acetylgalactosamine (Glycosynth,
Cheshire, England) were utilized as references for chemical shift
assignment. The NMR spectral data of the standard a and b meth-
ylated monosaccharides as well as those of GalNAc-ol reported by
Ishihara et al. [9] were also utilized as references for the chemical
shift assignment.
4.9. Mild periodate oxidation of oligosaccharides
To cleave the C–C bond of the reducing terminal GalNAc-ol at
positions C4 and C5, mild periodate oxidation of oligosaccharides
was performed according to the methods of Chai et al. [35]. The oli-
gosaccharides (approx. 10 lg) were oxidized with sodium perio-
date in imidazole buffer, pH 6.5, at 0 C for 5 min. After excess
periodate was destroyed by incubation with butane-2,3-diol at
0C for 40 min, the oligosaccharides were puriﬁed with a column
of graphitized carbon.
4.10. ELISA and competitive ELISA
The microtiter plates were coated with 2–200 ng of the puri-
ﬁed mucin and kept overnight at 4 C followed by blocking with
2% skimmed milk [8]. In case of using 2–200 ng of GM2 gangli-
oside (Alexis Corporation, Lausen, Switzerland) as antigen, the
coated wells were blocked with 1% BSA for overnight. After the
wells were washed, a deﬁnite amount of HCM31, KM694 or
GMB28 was added to each well followed by incubation at ambi-
ent temperature for 1 h. The wells were successively incubated
with horseradish peroxidase (HRP)-conjugated goat anti-mouse
immunoglobulins (Dako, Kyoto, Japan) and 2,20-azino bis-[3-eth-
ylbenzthiazoline-6-sulfonate] (ABTS)/H2O2 solution (Kirkegaard &
Perry Laboratories, Inc., Gaithersburg, MD, USA), and the color
was allowed to develop. The wells were washed three times
with PBS containing 0.05% Tween-20 for mucin or PBS for GM2
between each process. The UV absorption was measured at
405 nm (reference at 492 nm) at 30 min thereafter using a
Bio-Rad Model 550 microplate reader.
A competitive ELISA was applied to detect the reactivity of
HCM31 with the oligosaccharide fractions. The microtiter plates
coated with 100 ng of the puriﬁed mucin followed by blocking
with 2% skim milk were prepared as previously mentioned. At
the same time, PBS solutions of the oligosaccharide fraction, each
containing 0.15–10 lg or 0.15–75 nmol per well as the hexose
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with a deﬁnite amount of HCM31 for 2 h at ambient tempera-
ture. Instead of the sugar-containing solution, PBS was pre-incu-
bated with HCM31 as the negative control. The pre-incubated
mixtures were then added to the antigen-coated wells and incu-
bated for 1 h. The remaining ELISA steps were the same as al-
ready described.
4.11. Periodate treatment and trypsin digestion of mucins
Periodate treatment was performed by exposing the mucin
coated on the microtiter wells to 0.1–2.5 mM NaIO4 in 50 mM so-
dium acetate, pH 4.5, for 1 h at room temperature. Trypsin diges-
tion was performed by exposing the mucin coated on the
microtiter wells to trypsin for 1 h at 37 C. Trypsin at 2.5 mg/ml
in 10 mM Tris–HCl, pH 8.0, containing 2 mM CaCl2 was used with
two-fold serial dilution. Each of the remaining ELISA steps was the
same as already described.
4.12. Immunohistochemistry
Human tissues (20% formalin-ﬁxed, routinely processed, and
parafﬁn-embedded) were selected from the surgical pathology ﬁles
of the Department of Laboratory Medicine, Shinshu University
Hospital, Matsumoto, Japan. The following histologically normal
tissues were selected: bronchi (n = 6), esophagus (n = 5), gastric
fundic mucosa (n = 6), gastric pyloric mucosa (n = 6), duodenum
(n = 6), cecum (n = 4), sigmoid colon (n = 4) and rectum (n = 1).
The cancer tissues of cecum (n = 5), sigmoid colon (n = 4) and rec-
tum (n = 1) were also selected. In addition, the proximal half of rat
small intestine, deﬁned as the jejunum, was resected and immedi-
ately ﬁxed for 3 h in freshly prepared Carnoy’s solution according
to the method described previously [36]. After ﬁxation, the jeju-
num was routinely processed and embedded in parafﬁn.
From these specimens, 3 lm parafﬁn sections were prepared for
immunostaining with HCM31. Immunohistochemical staining was
performed using the immuno-enzyme polymer method (Histoﬁne
Simple Stain MAX PO Multi, Nichirei Biosciences, Tokyo, Japan)
with 3,3-diaminobenzidine as the chromogen. Brieﬂy, endogenous
peroxidase activity was blocked with 0.3% H2O2, then the speci-
mens were sequentially incubated with the mAb, HRP-conjugated
immuno-enzyme polymer, and 0.02% 3,3-diaminobenzidine in 50
mM Tris–HCl, pH 7.6, containing 0.005% H2O2. Counterstaining
was performed with hematoxylin.
4.13. Sialidase treatment and de-O-acetylation for the specimens
Enzymatic treatment was performed by exposing the speci-
mens for immunostaining to 0.1 units of a2-3,6,8-sialidase from
Arthrobacter ureafaciens (Nacalai Tesque, Kyoto, Japan) in 10 mM
sodium phosphate, pH 5.0, for 4 h at 37 C.
De-O-acetylation treatment of sialic acid was performed by
exposing the specimens to 0.2 M NaOH at 37 C for 2 h.
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